Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs

Mini Rev Med Chem. 2011 Mar;11(3):214-24. doi: 10.2174/138955711795049844.

Abstract

Cisplatin and its congeners are well-known to exert their therapeutic effects on cancer via interaction with DNA in the cell nucleus. On the other hand, the undesirable side-effects of these drugs appear to also be linked, at least to some extent, to interaction of the platinum with proteins and peptides. For other classes of anticancer drugs, interaction with proteins is in fact the primary pathway whereby therapeutically-useful effects are achieved. Here, a review is given of the known instances of interaction of cisplatin and related compounds with proteins and biologically relevant peptides, with emphasis on structural and reactivity aspects.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents / toxicity
  • Cisplatin / chemistry*
  • Cisplatin / therapeutic use
  • Cisplatin / toxicity
  • Humans
  • Neoplasms / drug therapy
  • Organoplatinum Compounds / chemistry*
  • Organoplatinum Compounds / therapeutic use
  • Organoplatinum Compounds / toxicity
  • Protein Binding
  • Proteins / chemistry*
  • Proteins / metabolism

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Proteins
  • Cisplatin